In:
European Archives of Oto-Rhino-Laryngology, Springer Science and Business Media LLC, Vol. 278, No. 11 ( 2021-11), p. 4411-4421
Kurzfassung:
Salivary gland carcinomas (SGC) cover a heterogeneous group of malignancies with a lack of data of high-level evidence. Methods Clinical data of 127 patients treated for SGC at a university cancer center between 2002 and 2017 were analyzed retrospectively. The association of clinicopathological characteristics, treatment modalities, adverse events, and outcome was assessed. Results Patients received surgery ( n = 65), surgery followed by (chemo-)radiotherapy ( n = 56), or primary (chemo-)radiotherapy ( n = 6). Injury to the cranial nerves or their branches was the most frequent surgical complication affecting 40 patients (33.1%). Ten year overall and progression-free survival rates were 73.2% and 65.4%, respectively. Parotid tumor site, advanced tumor, and positive nodal stage remained independent negative prognostic factors for overall survival, loco-regional and distant tumor control in multivariate analysis. Conclusions Optimizing treatment strategies for SGC, depending on distinct clinicopathological factors, remains challenging due to the low incidence rates of the disease.
Materialart:
Online-Ressource
ISSN:
0937-4477
,
1434-4726
DOI:
10.1007/s00405-021-06652-5
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2021
ZDB Id:
1459042-6
Bookmarklink